期刊文献+

胸腺五肽结构修饰进展 被引量:2

Progress in research of the structural modification of thymopentin
原文传递
导出
摘要 胸腺五肽(TP5)由胸腺生成素活性中心的5个氨基酸组成,作为免疫平衡调节剂广泛应用于临床。TP5在体内稳定性差、易被酶解、半衰期极短,导致其所具有的生物活性在临床应用中难以充分发挥。通过结构修饰研发TP5衍生物,提高产物的体内抗酶解能力及生物利用度,更好地发挥其生物活性,是研发新型高效免疫平衡调节剂的重要方向。文中针对TP5进行结构修饰的研究进展,包括氨基酸序列的调整与取代、端基化学修饰与肽键替换、反转类似物及环肽的设计与合成、TP5偶合物的研制等。 Thymopentin (TP5) is constituted with the 5 amino acids at the active center of thymopoietin, and used to treat immune disharmony widely in clinic. TP5 is unstable, can be easily lyzed by enzymes and has short half life in vivo; therefore, its biological activity is obviously reduced. Modification of TP5 structure includes the amino acid replacement and sequence adjustment, the terminal group modification and peptide bond alteration, the retro-inverso analogues, and design and syntheses of cyclic derivatives, and the preparation of TP5 conjugates. The new modified TP5 derivatives possess good stability and strong anti-enzymolysis ability in vivo. This is an important strategy for the research and development of new immunomodulators with higher biological activity.
作者 陈艳丽 王朴
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第10期895-899,共5页 Chinese Journal of New Drugs
基金 山东大学海外引进高层人才启动基金(No.065960114)
关键词 胸腺五肽 免疫调节剂 结构修饰 稳定性 thymopentin immunoinodulator structural modification stability
  • 相关文献

参考文献26

  • 1GOLDSTEIN G, AUDHYA TK. Thymopoietin to thymopentin: experimental studies [ J ]. Surv Immunol Res, 1985, 4 ( Suppl 1):S1-S10.
  • 2李小玲,张美荣,武金旦,曹翠珍.胸腺五肽联合干扰素治疗慢性乙型肝炎临床观察[J].现代中西医结合杂志,2006,15(6):777-777. 被引量:5
  • 3MERIGAN TC, HIRSCH RL, FISHER AC, et al. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4 + T cells on progression of HIV disease in a double-blind study of thymopentin[ J ]. Aids, 1996, 10(2): 159-165.
  • 4卢岳青,贡联兵,佟东宁.3485例应用胸腺五肽预防SARS的疗效分析[J].中华临床医药杂志(北京),2004,5(3):109-110. 被引量:7
  • 5TISCHIO JP, PATRICK JE, WEINTRAUB HS, et al. Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma[J]. Int J Pept Protein Res, 1979, 14(5) :479 -484.
  • 6HEIZMANN J, LANGGUTH P, BIBER A, et al. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes [ J ]. Peptides, 1996, 17 ( 7 ) : 1083 - 1089.
  • 7HUSSAIN MA, KOVAL CA, SHENVI AB, et al. An aminoboronic acid derivative inhibits thymopentin metabolism by mucosal membrane aminopeptidases [ J ]. Life Sci, 1990, 47 ( 3 ) : 227 -231.
  • 8WANG J, LU WL, LIANG GW, et al. Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers [ J ]. Peptides, 2006, 27 (4) : 826 - 835.
  • 9YUAN XJ, ZHANG ZR, SONG QG, et al. Research on thymopentin loaded oral N-trimethyl chitosan nanoparticles [ J ]. Arch Pharm Res, 2006, 29(9) :795 -799.
  • 10ZHENG AP, WANG JC, LU WL, et al. Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics[ J ]. J Nanosci Nanotechnol, 2006, 6(9-10): 2936-2944.

二级参考文献36

  • 1王德心.固相同步多重肽合成[J].有机化学,1994,14(1):12-18. 被引量:5
  • 2程林,万坚.肽酰转移酶催化肽键形成机理的理论计算研究[J].华中师范大学学报(自然科学版),2006,40(1):60-62. 被引量:2
  • 3Pinilla C, Appel JR, Campbell GD, et al. All-d peptides recognized by an anti-carbohydrate antibody identified from a positional scanning library[J]. J Mol Biology, 1998,283(5): 1013-1025.
  • 4Boutin JA, Fauchere AL. Combinatorial peptide synthesis: statistical evaluation of peptide distribution [ J ]. Trends in Pharmacological Sciences, 1996,17(1): 8-12.
  • 5Rodda SJ, Tribbick G. Antibody-defined epitope mapping using the multipin method of peptide synthesis [ J ]. Methods, 1996,9(3): 473-481.
  • 6Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody inteation at the level of individual amino acids [ J ]. Proc Natl Acad Sci USA,1985,82(15):5131-5135.
  • 7Kit SL, Douglas L, Sydney ES, et al. A one-bead one peptide combinatorial library method for B-cell epitope mapping[J]. Methods,1996,9(3):482-493.
  • 8Ronald F. The spct-synthesis technique: synthetic peptide arrays on membrane supports-principles and applications [J]. J Immunological Methods, 2002,267(1): 13-26.
  • 9Kaiser E, Co lescott RL, Bossing CD, et al. Color test for detection of terminal amino groups in the solid phase synthesis of peptides[J].Anal Biochem, 1970,34(2): 595-600.
  • 10张定风.乙型肝炎病人血清抑制因子对干扰素诱生的影响[J].中华医学杂志,1984,64(5):273-273.

共引文献16

同被引文献25

  • 1王良友,潘和平,柳川,高亚萍.人甲状旁腺素(1-34)的合成与聚乙二醇化修饰[J].中国生化药物杂志,2005,26(2):76-79. 被引量:6
  • 2欧阳嘉,李鑫,潘宗敏,沈树宝.Fmoc(9-芴甲氧羰基)法固相合成胸腺五肽[J].南京工业大学学报(自然科学版),2005,27(3):61-64. 被引量:12
  • 3Goldstein G,Scheid M P,Boyse E A,et al.A synthetic entapoptide with biological activity characteristic of the thymic hormone thymopoietin[J].Science,1979,204(4399):1309-1310.
  • 4Gonser S,Weber E,Folkers G.Peptides and polypeptides as modulators of the immune response:thymopentin-an example with unknown mode of action[J].Pharm Acta Hely,1999,73(6):265-273.
  • 5Tiachio J P,Patrick J E,Weintraub H S,et al.Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma[J].Int J Pept Protein Res,1979,14(5):479-484.
  • 6Wang J,Lu W L,Liang G W,et al.Pharmacokinetics,toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers[J].Peptides,2006,27(4):826-835.
  • 7Ynan X J,Zhang Z R,Song Q G,et al.Research on thymopentin loaded oral N-trimethyl chitosan nanoparticles[J].Arch Pharm Res,2006,29(9):795-799.
  • 8Zheng A P,Wang J C,Lu W L,et al.Thymopentin-loaded pH-sensitive chitozen nanoparticles for oral administration:reparation,characterization,and pharmacodynamics[J].J Nanosci Nanotechnol,2006,6(9210):2936-2944.
  • 9YinY S,Chen D W,Qiao M X,et al.Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin[J].J Controlled Release,2006,116(3):337-345.
  • 10Wang Y S,Youngster S,Grace M,et al.Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications[J].Adv Drug Deliv Rev,2002,54(4):547-570.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部